---

$4.50

-0.0650 ( -1.42% ) 34.0K

NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-05-23	Buy	675.00	GARNETT KEITHLY
2025-05-23	Buy	2759.00	CHEN THOMAS C
2025-05-23	Buy	2000.00	Heshmatpour Amir F
2025-05-22	Buy	135.00	GARNETT KEITHLY
2025-05-19	Buy	1600.00	Heshmatpour Amir F
2025-05-19	Buy	400.00	CHEN THOMAS C
2025-05-19	Buy	90.00	GARNETT KEITHLY